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DOSE SPARING INTRADERMAL TRIVALENT INFLUENZA (2010/2011) 
VACCINATION OVERCOME REDUCED IMMUNOGENICITY OF THE 2009 H1N1 
STRAIN* 
IFN Hung, YT Levin, KKW To, KH Chan, AJ Zhang, P Li, C Li, T Xu, TY Wong, KY Yuen 
 
Department of Medicine, the University of Hong Kong, Carol Yu’s Centre for Infection and 
Division of Infectious Diseases, the University of Hong Kong, Queen Mary Hospital, Queen 
Mary Hospital, Hong Kong 
 
BACKGROUND: We hypothesised that low-dose intradermal (ID) vaccination of the trivalent 
influenza vaccine (TIV) delivered by the MicronJet600TM (NanoPass Technologies, Israel) 
would be non-inferior to the full-dose intramuscular (IM) and mid-dose IntanzaR vaccination in 
the elderly and the chronically ill adults. 
 
METHODS: We performed a prospective randomised trial on elderly and chronically ill adults. 
Subjects were randomly assigned into four groups. Groups ID3 and ID9 received reduced dose ID 
TIV (3 μg and 9 μg of haemagglutinin per strain respectively) delivered by MicronJet600TM 
(NanoPass Technologies, Israel). Group INT9 received reduced-dose ID TIV (9 μg) delivered by 
Becton Dickinson’s SoluviaTM device (IntanzaR9, Sanofi-Pasteur, France). Control group IM15 
received a full-dose IM TIV (15 μg). We measured antibody titres by haemagglutination 
inhibition (HAI) and microneutralisation (MN) assays at baseline and day 21. 
 
RESULTS: Baseline characteristics for all groups were similar (group and sample sizes: ID3=63; 
ID9=68; INT9=65; IM15=66). At day 21 post-vaccination, the GMT ratio and the seroconversion 
rates difference for all three strains of the ID vaccine groups were non-inferior to the IM vaccine 
group. The seroconversion rate, seroprotection rate, and the GMT of the H1N1 strains by HAI 
and MN assays were significantly higher in the ID groups compared with the full-dose IM 
vaccine group. The seroconversion rates of the H3N2 strain by HAI assay were also significantly 
higher in the ID groups when compared with the full-dose IM group. Direct comparison among 
the three ID devices showed no significant differences. No serious adverse events related to 
vaccination were reported. 
 
CONCLUSION: Dose-sparing ID TIV can overcome reduced immunogenicity of the H1N1 
strain, and according to some measures, for the H3N2 strain. At-risk subjects indicated for the 
TIV should be considered for intradermal immunisation to compensate for reduced 
immunogenicity. 
 
* Manuscript published in Vaccine 2012;30:6427-35. 
